Peripheral Neuropathy Clinical Trial
— FRT-PNOfficial title:
To Prove the Effectiveness of PENS Therapy With Peripheral Neuropathy
Verified date | September 2018 |
Source | DyAnsys, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
Status | Active, not recruiting |
Enrollment | 66 |
Est. completion date | October 2018 |
Est. primary completion date | September 15, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Patients with Neuropathy pain Exclusion Criteria: - Patient with inbuilt pacemakers or any other devices which allows current into the body, pregnant ladies. |
Country | Name | City | State |
---|---|---|---|
India | Clinic | Warangal | Telangana |
Lead Sponsor | Collaborator |
---|---|
DyAnsys, Inc. |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Complete reduction of conditions associated with peripheral neuropathy | After the overall treatment has been completed the conditions associated with peripheral neuropathy will be completely reduced and the occurrence of the pain will be stopped which can be verified and evaluated through "Biothesiometer" parameters. | 7 weeks | |
Primary | Reduction of Neuropathy pain | This treatments effective outcome will be, "Percutaneous Electrical Nerve Stimulation therapy will have the ability to reduce the pain and other conditions regarding peripheral neuropathy" which can be verified through "Biothesiometer" parameters. | According to the patients condition and other factors expected to reduce pain in 4th week of the treatment | |
Secondary | Check for delay of Re-occurrence of pain within a short time | After the treatment of 4th week the pain will be reduced and the treatment is continued for other 3 weeks where the booster dose is applied for the assurance of delay of pain which is evaluated manually by the medical personals after 90 days of booster dose treatment | 90 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05152368 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy
|
Phase 1 | |
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Completed |
NCT02549534 -
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02701075 -
MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain
|
N/A | |
Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
Completed |
NCT00763087 -
Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet
|
N/A | |
Completed |
NCT00079807 -
Painful HIV Neuropathy and Alpha-Lipoic Acid
|
Phase 1/Phase 2 | |
Completed |
NCT03292328 -
Yoga for Symptoms of Nerve Damage Caused by Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05379140 -
Use Therapeutic Chinese Massage to Treat Peripheral Neuropathy in People With HIV
|
N/A | |
Recruiting |
NCT05673746 -
Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer
|
N/A | |
Completed |
NCT05189535 -
"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
|
Phase 2/Phase 3 | |
Recruiting |
NCT06219590 -
Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy
|
N/A | |
Enrolling by invitation |
NCT05595109 -
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
|
Phase 2/Phase 3 | |
Completed |
NCT05916118 -
Exercise and Oxaliplatin-induced Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT03881748 -
Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
Completed |
NCT02936843 -
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
|
Phase 2/Phase 3 | |
Terminated |
NCT01458015 -
Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01006408 -
Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy
|
N/A | |
Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 |